Hotung Inv: The Hotung Phoenix® spring clip obtained NMPA approval in advance, once again confirming its efficient R&D strength.

On September 27, China's leader in the field of peripheral and vascular intervention$ZYLOXTB (02190.HK)$announced that its subsidiary Zhuhai hotung inv Medical Technology Co., Ltd. (hereinafter referred to as 'hotung inv Medical') independently developed hotung invose Spring Coil System has been approved for marketing by the National Medical Products Administration (NMPA), ahead of the expected approval time disclosed in the mid-term performance report in the fourth quarter of 2021, marking a new phase for hotung inv Medical in the interventional treatment of hemorrhagic cerebrovascular diseases.

The hotung invose Spring Coil System is an ultra-soft mechanical detachment spring coil, with the advantages of super softness, mechanical detachment, and complete specifications. Clinical trial data before market launch showed that the softness of the hotung invose Spring Coil is comparable to the latest generation products of the leading international brands, and can safely and densely fill irregular arterial aneurysms and ruptured arterial aneurysms.

Compared to the European and American populations, Chinese intracranial aneurysms generally present the characteristics of 'small tumors and thin-walled parent arteries'. However, the current market for aneurysm embolization spring coils is still dominated by imported products, with a domestic substitution rate of less than 10%, urgently needing an ultra-soft spring coil suitable for Chinese people. The market launch of the hotung invose Spring Coil fills this market gap. The hotung invose Spring Coil has a softer coil body, a smoother push system, can better adapt to the tumor morphology, and improve surgical safety and embolization effectiveness.

At the same time, the hotung invose Spring Coil adopts a mechanical detachment structure, compared with the electrolytic detachment and hydrolytic detachment methods, the detachment process is simple, quick, safe, and reliable. The operator only needs 'one bend and one pull' to detach instantly, with an average detachment time of less than 1 second.

In terms of models, the hotung invose Spring Coil System has a very complete range of specifications, including 6 models with 1mm sizes, which can cover most complex lesions, providing more choices for embolization of small arterial aneurysms, and offering a comprehensive embolization treatment plan for patients and doctors.

With the aging of the Chinese population intensifying and the rapid development of domestic neurointerventional technology, China's neurointerventional medical device market is growing rapidly. The 'China Stroke Prevention and Control Report (2020)' points out that the detection rate of intracranial aneurysms in China is as high as 7%, and is showing an upward trend year by year. According to Frost & Sullivan analysis, the number of intracranial aneurysm intervention surgeries in China will increase from 0.052 million units in 2018 to 0.0737 million units in 2021, and further increase to 0.444 million units by 2030, with a huge market space.

Currently, as a subsidiary of Hotung Inv's Neurointerventional Business Unit, Hotung Medical is committed to providing a full product line solution covering ischemic and hemorrhagic strokes for Chinese stroke patients, with a total of 21 approved and under development products. As of September 2021, Hotung Medical has obtained NMPA approvals for 7 products. In the field of ischemic stroke, Hotung Jiaolong thrombectomy stent, Silver Snake intracranial support catheter, and Dayu balloon catheter have been launched, making them one of the few domestic manufacturers that can provide the BADDASS technology trilogy. In the field of hemorrhagic stroke, Hotung Feng spring coil has started commercialization, and the Kirin mesh stent with full visualization is in the pre-market clinical stage.

Since August, Hotung Inv's independently developed Hotung Jiaolong microcatheter and Hotung Feng spring coil have both obtained certification ahead of schedule, demonstrating its strong and efficient R&D capabilities. With the gradual realization of the R&D pipeline, Hotung Inv will provide patients and doctors with a more comprehensive and efficient product portfolio and solutions, allowing more patients to enjoy a high-quality life brought by advanced medical technology.

130K Views